Expression of Leukemia-Associated Antigen, JL1, in Bone Marrow and Thymus

Young Kee Shin,*† Eun Young Choi,* Seok Hyung Kim,* Junho Chung,‡ Doo Hyun Chung,* Weon Seo Park,§ Kyeong Cheon Jung,‖ Heung Sik Kim,‖ Seonyang Park,**, Hee Jin Kim,†† Myoung Hee Park,†‡ Chang Ki Min,‡‡ Chun Choo Kim,‡‡ and Seong Hoe Park*†

From the Departments of Pathology,* Internal Medicine,** Clinical Pathology,†† and Biochemistry,†† Seoul National University College of Medicine, Seoul; DiNonA Inc.,§ Suwon; the Department of Pathology,§ Kangwon National University College of Medicine, Chunchon; the Department of Pathology,‖ Hallym University College of Medicine, Chunchon; the Catholic HSCT Center,‖ St. Mary's Hospital, The Catholic University of Korea, Seoul; and the Department of Pediatrics,§ Keimyung University College of Medicine, Taeung, Korea

The identification of immunophenotypic markers with restricted expression has long been a critical issue in diagnostic and therapeutic advances for acute leukemias. We previously developed a monoclonal antibody against a new thymocyte surface antigen, JL1, and showed that JL1 is expressed in the majority of acute leukemia cases. In this study, using multiparameter flow cytometric analyses, we found that JL1 was uniquely expressed in subpopulations of normal bone marrow (BM) cells, implying the association of JL1 with the differentiation and maturation process. Although CD34+ CD10+ lymphoid precursors and some of maturing myeloid cells express JL1, neither CD34+ CD38−/lo nor CD34+ AC133+ noncommitted pluripotent stem cells do. As for the myeloid precursors, CD34+ CD33+ cells do not express JL1. During lymphopoiesis, JL1 on the earliest lymphoid precursors disappear in the CD20+ sIgM+ stage of B-cell development or after CD1a down-regulation in thymocytes. Despite the highly restricted expression of JL1 in normal BM cells, most of the leukemias express JL1 irrespective of their immunophenotypes. These results indicate that JL1 is not only a novel differentiation antigen of hematopoietic cells, but also a leukemia-associated antigen. Therefore, we suggest that JL1 be a candidate molecule in acute leukemia for the diagnosis and immunotherapy that spares the normal BM stem cells. (Am J Pathol 2001, 158:1473–1480)

Leukemia-specific phenotypes, identified by monoclonal antibodies (mAbs) recognizing various cell surface antigens, have long played essential roles in the diagnosis and classification of leukemia. Because the antigens found on certain leukemic cells are also expressed on the surfaces of the normal counterparts in a developmental stage-dependent manner, they can be used as markers for lineage and differentiation. For instance, differentiation antigens such as CD34, CD10 (CALLA), CD13, CD19, CD7, CD20, CD33, and CD13 that are expressed on specific subsets of normal hematopoietic cells have been used as diagnostic markers for leukemic cells. Therefore, the characterization of molecules on the surface of hematopoietic cells is critical for the diagnosis of leukemia as well as for the understanding of hematopoiesis.

Acute leukemia still remains a therapeutic challenge in medical practice even in the age of high cure rates for pediatric leukemia with the advent of intensification of chemotherapy along with hematopoietic stem cell rescue. It is therefore not surprising that alternative strategies, possessing distinct action mechanisms to complement currently used treatment approaches, are needed and immunotherapy has been an appealing candidate. In the past trials, mAb-based immunotherapy targeting leukocyte-specific antigens such as CD33, CD45, and CDw52 has been evaluated for the treatment of leukemia. Although immunotherapy might be an attractive approach for the treatment of patients with leukemia, all these antibody-based immunotherapies are dependent on limited antigenic properties themselves. As a consequence, it is worth trying to develop mAb(s) that recognize(s) specific antigen(s) with the restricted expression profile.

We previously reported a mAb against a novel human thymocyte differentiation antigen, designated as JL1, which is not expressed on mature T cells. We further showed that the anti-JL1 mAb broadly recognizes various types of acute leukemias of myeloid and B cell origins as well as T cell lineage. This strong co-relationship between JL1 positivity and the diagnosis of leukemia prompted us to investigate the expression pattern of JL1 antigen in normal leukocytes during hematopoiesis in

Supported by the 1999 BK21 project for Medicine, Dentistry, and Pharmacy, and the 99’ DiNonA Inc. R&D Project, Suwon, Korea.

Accepted for publication December 21, 2000.

Address reprint requests to Seong Hoe Park, Dept. of Pathology, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-799, Korea. E-mail: pshoe@plaza.snu.ac.kr.
detail. Although JL1 antigen was initially reported not to be expressed in the majority of normal unfractionated bone marrow (BM) cells, if not all, there remained a possibility that a small proportion of BM cells do express JL1, because of the high heterogeneity of mononuclear cells (MNCs) in normal BM. In the present study, to dissect the expression patterns of JL1 antigen on the leukocytes of different lineage and maturation stages in BM, cord blood (CB), and thymus, we fractionated the MNCs using lineage-specific markers and re-evaluated JL1 expression on their surfaces. We found that JL1 molecules are expressed on some of the precursor cells of lymphoid and myelomonocytic lineages but not on pluripotent stem cells. As most of the leukemias express JL1 antigen on the cell surfaces, anti-JL1 mAb may have the implications for the immunotherapeutic potential for the treatment of leukemia.

**Materials and Methods**

**Cell Preparation**

CB cells (n = 7) were obtained at Keimyung University Hospital, and normal (n = 3) or G-CSF-primed (n = 10) BM cells were aspirated from the posterior iliac crests of healthy adult and pediatric transplantation donors with written consents following guidelines approved by the Institutional Review Board for Human Research, Seoul National University Hospital in conformity with the Helsinki protocols. Recombinant human G-CSF (Filgrastim; Amgen, Thousand Oaks, CA) was administered subcutaneously at a dosage of 10 μg/kg/day for 3 consecutive days. Both BM aspirates and CB were drawn into 10-ml syringes containing 100 U of preservative-free heparin and then diluted with RPMI 1640 (Life Technologies, Inc., Grand Island, NY) supplemented with 100 U/ml penicillin/streptomycin (Life Technologies, Inc.). MNCs were isolated by density-gradient centrifugation on Ficoll-Hypaque (1077 g/cm³; Pharmacia-British classification). MNCs were isolated by Ficoll-Hypaque (1077 g/cm³; Pharmacia, Uppsala, Sweden). Normal thymic specimens (n = 5) were obtained from children (<3 years old) undergoing corrective cardiac surgery. Thymocyte single-cell suspensions were prepared, washed, and used for immunofluorescence staining.

**Antibodies**

The murine mAbs, anti-JL1, were produced and purified as previously described. Biotinylation of anti-JL1 mAb was performed with biotin hydrazine (Pierce, Rockford, IL) according to the manufacturer’s protocols. The directly labeled mAbs were purchased as follows: CD1a (YG19-FITC), CD4 (YG22-PE), CD8 (DN17-FITC), CD10 (D4-3-1-PE), CD16 (GRM-1-PE), CD19 (SJ25-C1-FITC, -PE), CD20 (B-Ly1-PE), CD33 (WM53-PE), CD45 (AP4-FITC), CD56 (ERIC-1-PE), and CD71 (RVS10-PE) from Dianova Inc. (Swansea, CA); CD23 (M-L233-PE), CD38 (HIT2-PE), IgD (IA6-2-PE), IgM (G20–127-PE) from PharMingen (San Diego, CA); AC133 (AC133/2-PE) from Miltenyl Biotec (Bergisch Gladbach, Germany). As for the control experiments, cells were incubated with fluorochrome-labeled isotype-matched controls (IgG1-FITC, -PE; Ig2a-FITC, -PE; biotinylated IgG1). For biotinylated antibodies, streptavidin-cychrome (PharMingen) were used as third fluorochrome for the analysis. Especially, JL1lo cells were well visualized, because cychrome-conjugated streptavidin has excellent quantum efficiency. All stained cells were analyzed using FACScalibur (BDIS) flow cytometry.

**Immunofluorescence Staining and Flow Cytometric Analysis**

Three-color flow cytometric analysis was used for anti-JL1 mAb screening. The 10⁶ cells were first incubated with biotinylated mAbs in phosphate-buffered saline (PBS) containing 1% bovine serum albumin and 0.1% sodium azide for 30 minutes at 4°C. These cells were then washed with PBS and stained with cychrome-conjugated streptavidin. To minimize nonspecific staining in three-color fluorescence-activated cell sorting (FACS) analysis, this step was followed by incubation with unla-beled irrelevant-murine IgG1 (MOPC21; Sigma, St. Louis, MO) or mouse serum (DAKO, Carpinteria, CA). After indirect staining, relevant fluorochrome-labeled mAbs were used. Before analysis, the cell suspension was passed through a 30-μm nylon mesh (Swiss Silk Bolting Mfg. Co., Zurich, Switzerland). Flow cytometric analysis was performed on a FACScalibur (BDIS) equipped with an argon laser tuned with 488 nm. Forward light scattering, orthogonal light scattering, and fluorescence signals (FL-1-FITC, FL-2-PE or -Red613, FL-3-cychrome) were stored in list mode data files. Results were analyzed for at least 10,000 cells (10,000 to 30,000 cells) per test using the CellQuest software program (BDIS).

**Immunophenotyping of Leukemia and Statistical Analysis**

To analyze JL1 expression in leukemic cells from the clinical material, BM specimens from the consecutive patients diagnosed as leukemia in the Seoul National University Hospital were used. The classification of the acute leukemia was made according to the French-American-British classification. MNCs were isolated by Ficoll-Hypaque density gradient centrifugation. The immunophenotype of the leukemic cells was determined by the same method described previously. According to the standard criteria, samples were considered positive when the percentage of stained cells exceeded that of the control by at least 20%. Expression of JL1 or CD34 antigen in leukemia cases was given as a percentage of positive cases. For the statistical analysis of correlation, the expressions of JL1 and CD34 antigens were considered as discontinuous variables. All chi-square P values indicated were two-tailed and reported as statistically
significant if less than 0.05. The processing and statistical analysis of the data were performed with the software SPSS V6.1.2. (SPSS, INC., Chicago, IL).

Results

JL1 Expression of Lineage-Committed Leukocytes in BM

JL1 expression in fresh BM MNCs was investigated using multiparameter FACS analysis with a panel of conjugated mAbs directed against leukocyte surface antigens. Although we previously reported that JL1 antigen was not detectable in unfractionated BM cells, we have reproducibly observed a minimal subpopulation of JL1-expressing cells in subsequent experiments. To confirm the presence of JL1+ subpopulations in BM cells, we first performed FACS analysis with a use of CD45 intensity side-scatter gating and painting and identified JL1+ cells in various leukocyte lineages. As shown in Figure 1, BM MNCs were able to be separated into four distinct clusters such as lymphoid lineages (R1), myelomonocytic lineage (R2), early precursors (R3), and nucleated erythroid cells including nucleated red blood cells (R4). The types of corresponding leukocytes in each of the gated regions were confirmed by staining with the respective lineage markers (data not shown). JL1+ cells were detected in CD19+ B cells and CD34+ early precursors, whereas CD3+ T cells, CD16+ NK cells, and nucleated erythrocytes did not express JL1 antigen. The expression pattern of JL1 in the myelomonocytic region was heterogeneous and divided into three subgroups (Figure 3, see below). These results were also observed in CB MNCs (data not shown).

JL1 Expression in CD34+ Cells of Human BM and CB

The proportion of JL1+ cells showed a great interdonor variation (5 to 50%) in the early precursor compartment, and was remarkably reduced in CB MNCs (1 to 10%) (data not shown). We correlated JL1 reactivity with the expression of CD34, along with those of AC133, CD38, CD10, CD33, and CD71 to allow identification of noncommitted and various lineage-committed progenitor cells (Figure 2). Pluripotent stem cells were defined as CD34+CD133+ or CD38−/dimCD34+ cells in BM or CB, and they did not express JL1 molecules at all. In addition, JL1 was not expressed on CD34−CD33+ cells that contain virtually all colony-forming cells such as progenitor cells capable of forming granulocytes, erythrocytes, monocytes, megakaryocytes (CFU-GEMM), CFU-GM, and burst-forming unit erythrocytes (Figure 2B). CD34+CD71bright erythroid-committed progenitor cells were also JL1-negative (Figure 2B). In contrast, as shown in Figure 2B, the expression of JL1 antigen was observed on the majority of lymphoid-committed CD10+CD34+ precursors.

The expression profile of the JL1 molecule in CD34+ CB cells was almost same as that in BM cells. However, less CD34+ cells were JL1-positive as compared with that in BM cells (data not shown), and these results are directly attributed to the fact that there are less AC133+ CD34+ cells in CB MNCs. Therefore, these data indicate that JL1 expression is restricted to only lymphoid precursor cells among the CD34+ BM or CB MNCs.
myeloid-lineage were enriched by G-CSF administration and they were subdivided on the basis of CD33 and CD45 expression intensities. CD33 positivity is strong on promonocytes and monocytes (R5 in Figure 3); median on promyelocytes, myelocytes, and metamyelocytes (R6); and dim on band forms (R7). CD33\textsuperscript{med} promyelocytes, myelocytes, and metamyelocytes showed none or only dim expression of JL1. Most remarkably, the CD33\textsuperscript{dim} band forms expressed JL1 at high levels, whereas mature granulocytes were completely JL1-negative (data not shown). JL1 was also expressed on proportions of CD33\textsuperscript{bright} promonocytes, whereas peripheral monocytes did not express JL1 antigen (data not shown).

JL1 Expression and B-Cell Differentiation in Human BM

The coordinate expression of the markers such as CD34, CD19, CD20, and CD45RA has been exploited to characterize the developmental pathway of B lymphopoiesis in BM, and the development of B cell precursors could be divided into three major stages. To investigate the relationship between the expression of JL1 molecule and B cell development, cells of lymphoid and precursor-rich regions (R1 and R3 gate in Figure 1) were only analyzed, and mAbs against CD19 and surface-IgM (sIgM) were included in the staining protocols.

As shown in Figure 4, at least three major stages of B cell differentiation could be identified. The earliest B lineage cells are characterized by their expression of CD34 and CD19, and these CD34\textsuperscript{+}CD19\textsuperscript{+} cells showed a high level of JL1 expression. The next stage B cell precursors, characterized by the loss of CD34 expression, weak CD10 expression, and intermediate CD45RA density (CD45RA\textsuperscript{int}) on their surfaces, can be subdivided into two subsets, CD20\textsuperscript{dim}sIgM\textsuperscript{2} cells and CD20\textsuperscript{high}sIgM\textsuperscript{1} cells.
JL1 Expression and T Cell Differentiation in Human Thymus

Because T cell development in human thymus proceeds along the sequential acquisition and loss of the antigens such as CD34, CD1a, CD3, CD4, and CD8, their expression pattern has been used to assess the differentiation pathway of T lymphocytes (Figure 5). When JL1 expression was analyzed for T-cell differentiation stage, the expression of JL1 was detected from the earliest CD34+CD10− lymphoid precursor cells and disappeared in the CD20+CD8−/low immature cortical thymocytes (Figure 5, A and B). Most remarkably, the JL1 expression disappeared after CD1a down-regulation in single-positive CD3+CD4+ thymocytes (Figure 5C). CD1a+CD4+CD8− immature cortical thymocytes displayed the highest JL1 density on their surfaces among all leukocytes (Figure 5B). In addition, a subpopulation of CD3+CD4+CD8− thymocytes did not express JL1 antigen and this subset included virtually all of the CD56+ NK cells (data not shown).

JL1 Expression in Leukemia

As summarized in Table 1, JL1 antigen was expressed on more than 20% of blast cells in 181 (87.0%) of 208 leukemia cases and was effective for the detection of leukemias regardless of the phenotype. However, in sIg− non-T-ALL, JL1 positivities were significantly lower than the other subtypes, which is in accordance with the JL1 expression pattern in BM. JL1 positivity was slightly higher than CD34 positivity (76.4%) in all types of leukemia, and this difference is attributed to higher positivity of JL1 antigen in non-T-ALL (P = 0.027). No statistically significant co-relationship was observed between expression of JL1 and that of CD34 in leukemia. Most of the JL1-positive leukemias, including AML, however, expressed CD34 molecules. Furthermore, either JL1 or CD34 was expressed in most of leukemia cases tested, indicating that flow cytometric analysis using both anti-JL1 and anti-CD34 mAbs might be able to detect almost all types of leukemia.

Discussion

JL1 was discovered during the development of mAbs recognizing human thymocyte-specific antigens. JL1 is detectable on cortical thymocytes but not on peripheral lymphocytes. In earlier studies using unfractionated human BM, subsets of JL1-positive cells were not readily detected. In the present study, we re-examined the level of the expression of JL1 antigen on human leukocytes in BM, CB, and thymus using a multiparameter flow cytometric analysis, to reveal the level of its expression in CD34+ and other lineage-committed precursor cells. Especially, immunostaining was performed in a biotin-streptavidin complex cyochrome system to increase the sensitivity of the detection of JL1 antigen. In this study, we provide the evidence that JL1 antigen is a novel differentiation antigen and its expression is restricted to certain subsets of lymphoid and myeloid lineages and not expressed on pluripotent stem cells in BM and CB.

Currently available antigen to identify the pluripotent and progenitor cells in human BM is CD34. The CD34+ population in BM, however, represents heterogeneous

---

Table 1. FACS Profiles of Anti-CD34 and Anti-JL1 mAb Immunofluorescence in Leukemia

<table>
<thead>
<tr>
<th>Type of leukemia</th>
<th>Percent of JL1+ cases</th>
<th>Percent of CD34+ cases</th>
<th>Percent of CD34+ JL1+ cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>AML</td>
<td>90.1 (82*/91†)</td>
<td>83.5 (76/91)</td>
<td>76.9 (67/91)</td>
</tr>
<tr>
<td>M0</td>
<td>33.3 (1/3)</td>
<td>100.0 (3/3)</td>
<td>33.3 (1/3)</td>
</tr>
<tr>
<td>M1, M2</td>
<td>97.4 (38/39)</td>
<td>92.3 (36/39)</td>
<td>89.7 (35/39)</td>
</tr>
<tr>
<td>M3</td>
<td>100.0 (7/7)</td>
<td>42.9 (3/7)</td>
<td>42.9 (3/7)</td>
</tr>
<tr>
<td>M4, M5</td>
<td>84.4 (27/32)</td>
<td>81.3 (26/32)</td>
<td>68.8 (22/32)</td>
</tr>
<tr>
<td>Others†</td>
<td>90.0 (9/10)</td>
<td>80.0 (8/10)</td>
<td>70.0 (7/10)</td>
</tr>
<tr>
<td>Non-T-ALL</td>
<td>80.9 (55/68)</td>
<td>64.7 (44/68)</td>
<td>61.8 (42/68)</td>
</tr>
<tr>
<td>CD10+</td>
<td>90.6 (48/53)</td>
<td>73.6 (39/53)</td>
<td>67.9 (36/53)</td>
</tr>
<tr>
<td>CD10−</td>
<td>83.3 (5/6)</td>
<td>66.7 (4/6)</td>
<td>66.7 (4/6)</td>
</tr>
<tr>
<td>slg+</td>
<td>22.2 (2/9)</td>
<td>11.1 (1/9)</td>
<td>11.1 (1/9)</td>
</tr>
<tr>
<td>T-ALL</td>
<td>87.0 (20/23)</td>
<td>70.0 (16/23)</td>
<td>60.9 (14/23)</td>
</tr>
<tr>
<td>Acute biphenotypic leukemia</td>
<td>100.0 (13/13)</td>
<td>84.6 (11/13)</td>
<td>84.6 (11/13)</td>
</tr>
<tr>
<td>CML in blast crisis</td>
<td>84.6 (11/13)</td>
<td>92.3 (12/13)</td>
<td>84.6 (11/13)</td>
</tr>
<tr>
<td>Total</td>
<td>87.0 (181/208)</td>
<td>76.4 (159/208)</td>
<td>71.2 (148/208)</td>
</tr>
</tbody>
</table>

*No. of positive cases.
†No. of cases tested.
‡Others included M6 (acute erythroleukemia), M7 (acute megakaryocytic leukemia), MDS (myelodysplasic syndromes), etc.

AML (acute myelogenous leukemia); M0 (acute myelogenous leukemia with minimal differentiation); M1 (acute myeloblastic leukemia without maturation); M2 (acute myeloblastic leukemia with maturation); M3 (acute promyelocytic leukemia); M4 (acute monomyelocytic leukemia); M5 (acute monocytic leukemia); non-T-ALL (non-T-cell acute lymphoblastic leukemia); T-ALL (T-cell acute lymphoblastic leukemia); CML (chronic myeloid leukemia).
cell subsets including erythroid-, lymphoid-, or monomyeloid-committed cells. CD34+ cells, therefore, were subject to further analysis on the basis of AC133 expression. The CD34+ AC133+ population is presently classified as pluripotent cells containing majority of the CFU-GM, a proportion of the CFU-Mix, and a minor population of burst-forming unit erythrocytes, whereas the remaining progenitor cells are included in CD34+ AC133− population.26 Interestingly, we found that expression of JL1 was completely absent on CD34+ AC133+ cells, whereas one-third of CD34+ AC133− cells were positive for JL1 antigen (Figure 2). These data indicate that JL1 antigen is expressed on some progenitor cells but not on pluripotent hematopoietic stem cells.

For further analysis of the CD34+ AC133− population to examine the expression patterns of JL1 molecule in terms of other surface markers in detail, the BM blasts were stained with CD34 and lineage-specific markers (Figure 2). CD34+CD33− cells contained all colony-forming unit erythrocytes except lymphoid progenitors. The lymphoid- and erythroid-committed progenitor cells are defined with high expression levels of CD10 and CD71, respectively.26 Whereas JL1 antigen appeared to be expressed on most of CD34+ CD10+ lymphoid precursors, CD34+ CD33+ cells and CD34+ CD71+ bright erythroid-committed cells were all JL1-negative (Figure 2). Therefore, the JL1− fraction of the CD34+ AC133− population consists of CD34+ CD33+ cells, and all lymphoid precursors are JL1-positive.

As CD34+ CD10+ population includes CD34+ CD10+ CD19− CD7+ early T-lineage cells, the lymphoid-lineage cells can be further divided into T and B cell lineages in terms of CD10 expression.38 In B lineage cells, the highest JL1 expression was seen in CD34+ CD19+ cells and a significant reduction of JL1 expression had a inverse relationship with the expression levels of CD20 and slgM at later stages. Similarly, it was observed that JL1 antigen was expressed from the earliest CD34+ CD1a− CD3+ thymic precursors to some of the mature single-positive medullary thymocytes during T cell development. Collectively, JL1 is likely to be firstly expressed from common lymphoid progenitors and widely distributed during lymphoid ontogenesis, and to be down-regulated at the time of the final maturation process because JL1 is not expressed on peripheral mature T or B cells.17 These suggest a possible role of the down-regulation of JL1 molecule in the completion of lymphocyte maturation.

In contrast to its expression in early developmental stages of lymphoid lineage, several interesting patterns of JL1 expression were observed in myelomonocytic lineage cells (Figure 3). The CD33dim band forms expressed JL1 at high levels, whereas the CD33med pro-monocytes, myelocytes, and metamyelocytes showed none or dim expression (Figure 3). CD33high promonocytes and maturing monocytes also showed low levels of JL1 expression. These findings, together with the fact that JL1 is not expressed on mature peripheral monocytes or granulocytes,17 suggest that JL1 antigen is expressed during the later maturation process in the case of myelomonocytic hematopoiesis.
Taken together, these results showed that JL1 antigen is specifically expressed at the earlier stages of B and T cell lineages as well as at the later stage of myelomonocytic cells in BM but not on pluripotent stem cells or not on mature peripheral blood cells (Figure 6). Most remarkably, despite the restricted pattern in its tissue distribution, anti-JL1 mAb recognizes various types of acute leukemias (Table 1). Therefore, it is likely that JL1 antigen possesses similar characteristics with the CD34 molecule, in that both molecules are expressed within a narrow range of differentiation during hematopoiesis and successfully detect leukemias on the other hand. This finding led us to suggest that JL1 can be applied as an alternative of CD34 in the diagnosis of leukemia, which is currently known to be the most valuable marker antigen in clinical application for the diagnosis and subclassification of leukemia. It is also important to note that JL1 and CD34 antigens were co-expressed in 87.9% of AML. This correlation implies the possibility that this peculiar immunophenotype of AML might be useful for monitoring minimal residual disease after treatment. The current strategy of monitoring minimal residual disease by immunological methods takes advantage of the ectopically co-expressing leukocyte markers on malignant cells, which is not observed in normal BM or PB cells. In this respect, JL1 antigen seems to fit well for this immunophenotypic marker because of the JL1 negativity on normal CD34+CD33+ BM cells. Such phenotypes can be identified by double- or triple-color staining techniques performed with mAbs conjugated to different fluorochromes.

Restricted expression of CD34 antigen on hematopoietic stem/progenitor cells makes the anti-CD34 mAb useful for the quantification and purification of stem/progenitor cells. Anti-CD34 mAb, however, could not be used for immunotherapy of leukemia, because CD34 is expressed on normal vascular endothelial cells as well as on pluripotent stem cells albeit its high expression in leukemia cells. In contrast, JL1 is expressed on various leukemias but not on hematopoietic stem cells or nonhematopoietic tissues. In addition, we recently developed gelonin-conjugated anti-JL1 immunotoxin, which was able to dramatically inhibit the proliferation of in vitro cultured leukemia cells (Bae YM, Shin YK, Park SH, Chung J, Kim SH, Lee I-S, Lee KM, Choi EY, Jung KC, Kim HS, Kim CW, Song HG, manuscript submitted for publication). Therefore, all these findings suggest that JL1 immunotoxin can be useful as a potential candidate for immunotherapy of acute leukemia with negligible damage to normal hematopoietic stem cells.

In this article, we described the expression profile of JL1 antigen on human leukocytes in BM, CB, and thymus in detail. JL1 antigen was expressed in a subpopulation of limited stages during hematopoietic differentiation process, including early lymphoid precursors and maturing myelomonocytic-lineage cells of the late stage. We also demonstrated that JL1 is not expressed on normal hematopoietic pluripotent stem cells. This unique distribution of JL1 antigen further supports our previous suggestion that anti-JL1 mAb might be a good candidate for diagnostic and therapeutic trials of acute leukemia.

Acknowledgments

We thank E. K. Kim (Seoul National University Hospital, Seoul, Korea) and S. K. Chung (Keimyung University Hospital, Taegu, Korea) for their helpful technical support.

References